Uzum mulls possible Hong Kong, Abu Dhabi or Nasdaq IPO in 2027

Uzum mulls possible Hong Kong, Abu Dhabi or Nasdaq IPO in 2027

Uzum, a leading biotech firm, is reportedly considering an initial public offering (IPO) in either Hong Kong, Abu Dhabi, or on the Nasdaq in 2027. The company, founded in 2020, focuses on treatments for central nervous system diseases such as epilepsy, insomnia, and Parkinson’s. Uzum has raised $180 million in 2021, with notable backers including 6 Dimensions Capital, Goldman Sachs Group Inc, HBM Healthcare Investments AG, and Mubadala Investment Co. [1]

The potential IPO comes at a time when the Hong Kong Special Administrative Region (HKSAR) has reasserted itself as a global IPO leader, particularly for healthcare and biotech firms. The Hang Seng Biotech Index has surged by about 100 percent since the beginning of 2025, indicating strong investor interest in the sector. [1]

Uzum’s strategic location in Shanghai and its partnerships with major investors and institutions, including Mubadala Investment Co, position it well for an IPO. The company's focus on innovative treatments for central nervous system diseases aligns with the growing demand for advanced healthcare solutions. [1]

The decision to list in Hong Kong, Abu Dhabi, or on the Nasdaq could be influenced by several factors, including regulatory environments, market conditions, and investor preferences. Hong Kong offers a robust regulatory framework and a large pool of investors, while Abu Dhabi and the Nasdaq provide access to institutional capital and established markets. [1]

Institutional crypto adoption is also on the rise, as evidenced by the recent $2 billion partnership between Abu Dhabi-based Lunate and Brevan Howard. This deal reflects the growing acceptance of crypto as a core institutional asset class, driven by regulatory clarity and favorable jurisdictions. [3]

Uzum’s decision to explore an IPO in 2027 could be a strategic move to capitalize on these favorable market conditions and attract further investment. The company’s focus on cutting-edge biotech treatments and its strong backing from leading investors make it a promising candidate for an IPO in any of the proposed markets. [1]

References:
[1] https://www.chinadailyasia.com/hk/article/618654
[2] https://www.ainvest.com/news/strategic-implications-lunate-2-billion-abu-dhabi-partnership-institutional-crypto-adoption-2508/